Sales recorded by US biotech giant Gilead Sciences (Nasdaq: GILD) in the third quarter of 2018 beat analysts’ expectations but were still down on the same period of 2017.
Revenue for the quarter was $5.6 billion, and while this was well ahead of the consensus prediction on Wall Street of $5.37 billion, it was 14% lower than a year earlier, with increased competition to Gilead’s hepatitis drugs a major factor in the decline.
Net income was $2.1 billion or $1.60 per diluted share in 2018 compared to $2.7 billion or $2.06 per diluted share in 2017’s third quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze